Ignite Creation Date:
2024-05-06 @ 4:52 PM
Last Modification Date:
2024-10-26 @ 2:17 PM
Study NCT ID:
NCT05111444
Status:
UNKNOWN
Last Update Posted:
2021-11-08
First Post:
2021-10-27
Brief Title:
Camrelizumab Plus Pyrotinib Plus Chemotherapy in Human Epidermal Growth Factor Receptor 2 Positive HER2 Advanced Gastric or Gastroesophageal Junction GEJ Adenocarcinoma
Sponsor:
Fudan University
Organization:
Fudan University
Organization Data
Organization:
Fudan University
Class:
OTHER
Study ID:
OBU-SH-GC-II-010
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Fudan University
Lead Sponsor Class:
OTHER
Responsible Party:
None
Responsible Party Title:
None
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
None
Old Name:
None
Old Organization:
None